인간 간 모델 시장 : 모델 유형, 세포원, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Human Liver Model Market was valued at USD 1.55 billion in 2024 and is projected to grow to USD 1.68 billion in 2025, with a CAGR of 8.53%, reaching USD 2.54 billion by 2030.

The development and refinement of human liver models has accelerated dramatically over the past decade, marking a pivotal moment in biomedical research and drug development. In an era where precision medicine and innovative therapeutic strategies are at the forefront, an in-depth understanding of liver models has become essential. This report delves into the evolution of liver models, examining the integration of advanced methodologies and emerging technologies that are redefining the approach to liver physiology, disease modeling, and toxicity assessment. As research challenges escalate and regulatory demands intensify, the need for models that closely replicate human liver functions is more urgent than ever. Researchers, clinicians, and decision-makers alike are now presented with sophisticated alternatives-ranging from traditional two-dimensional cultures to dynamic three-dimensional systems, each offering unique benefits and addressing specific limitations of conventional methods. The current landscape is characterized by a significant shift towards more complex and physiologically relevant in vitro environments, a transition driven by both technological ingenuity and an increasing demand for actionable data in preclinical testing. In this context, this report provides a structured exploration of the transformative shifts, segmentation nuances, regional trends, and key players that are collectively steering the future of human liver model research.

Transformative Shifts Driving the Evolution of Liver Model Technologies

Recent years have witnessed transformative shifts that are reshaping the human liver model landscape. Technological convergence in experimental biology, computational simulations, and bioengineering has led to the creation of models that mimic the complex architecture and functionality of the human liver with unprecedented accuracy. Significant advancements in tissue engineering have enabled researchers to build three-dimensional constructs that encapsulate cell-matrix interactions better than traditional two-dimensional cultures. Additionally, the integration of ex vivo and hybrid models has bridged conventional gaps by combining the realism of native tissue with the controllability of engineered systems. The advent of in silico modeling has further accelerated data analysis and prediction, allowing for real-time adjustments and improvements in model fidelity.

A noteworthy element in these transformative shifts is the iterative process of validation and optimization that is now integral to model development. This ensures that emerging models not only serve as effective platforms for drug discovery and toxicology studies but also provide robust tools for physiological investigations. On the technological front, automation and high-throughput screening have contributed heavily to accelerating these advances. As research continues to drive improvements in replicating the human liver's complex behavior, the paradigm shift towards more biologically relevant methods is also fueling increased collaboration between academia, industry, and regulatory agencies. These converging forces underscore the vibrant, dynamic nature of the industry, where continuous innovation meets rigorous scientific inquiry.

Key Segmentation Insights Shaping Market Dynamics

A deep dive into segmentation reveals several underlying trends that are instrumental in defining market dynamics and future growth trajectories. When analyzing the market based on model types, an array of distinct technologies is employed, including two-dimensional models, three-dimensional models, ex vivo models, hybrid constructs, in silico models, and liver organoids. Each model brings its own set of advantages in terms of biological relevance and scalability, enabling researchers to target specific challenges in drug discovery and toxicology studies. Complementarily, a segmentation based on cell source further distinguishes the market; choices range from immortalized liver cell lines and primary human hepatocytes to stem cell-derived models, each offering varying levels of physiological accuracy and reproducibility.

In addition, application-centric segmentation highlights the dual role of these models. While drug discovery remains a major application area-supported by the ability to simulate metabolic pathways and signaling cascades-the educational sector has significantly benefited from advancements in physiology and toxicology studies. This dual focus facilitates a comprehensive understanding of liver functionality and underlines new educational practices enhanced by real-world data. Moreover, the segmentation based on end users further segments the market into biotechnology companies, contract research organizations, pharmaceutical companies, and research laboratories. The diversity in end-user profiles not only reflects a broad adoption of these models across various sectors but also illustrates the growing need for tailored liver models that match the specific requirements of each segment. This multifaceted segmentation analysis ensures that stakeholders can identify tailored opportunities and address market gaps with precision.

Based on Model Type, market is studied across 2D Models, 3D Models, Ex Vivo Models, Hybrid Models, In Silico Models, and Liver Organoids.

Based on Cell Source, market is studied across Immortalized Liver Cell Lines, Primary Human Hepatocytes, and Stem Cell-Derived Models.

Based on Application, market is studied across Drug Discovery and Education. The Education is further studied across Physiological Studies and Toxicology Studies.

Based on End Users, market is studied across Biotech Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Laboratories.

Regional Analysis: Global Perspectives on the Liver Model Sector

Regional dynamics play a critical role in shaping the development and adoption of human liver models. Market analysis indicates that different regions are prioritizing different aspects of technological advancement and regulatory frameworks. For instance, in the Americas, robust investment in biotechnology and healthcare infrastructure has paved the way for rapid adoption of innovative liver models in both industrial and academic settings. The mature ecosystem in this region supports a high level of collaboration among stakeholders, driving advancements through coordinated research and development efforts.

In contrast, the combined regions of Europe, the Middle East, and Africa are witnessing tailored investments designed to overcome regional healthcare challenges while balancing ethical and regulatory considerations. In these areas, traditional research methodologies are increasingly giving way to more sophisticated, hybrid approaches that integrate both ex vivo and in silico techniques. Meanwhile, the Asia-Pacific region stands out for its focused emphasis on scalability and cost-effectiveness. Rapid economic growth coupled with an expansive network of research institutions has catalyzed new product development and increased the overall global footprint of human liver models. Taken together, these regional insights underscore how localized market forces and strategic investments shape the adoption of liver models across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Spotlight: Leading Industry Players in Liver Modeling

The competitive landscape of liver model development is marked by the presence of several forward-thinking companies that are redefining the field. Industry leaders such as Ascendance Bio and BioIVT LLC have emerged as innovator hubs, consistently pushing the boundaries of technology. Significant contributions from companies like Cellink Global by BICO Group AB and CN Bio Innovations Ltd. have brought advanced tissue engineering capabilities into sharper focus, while established names such as Corning Incorporated demonstrate an enduring commitment to quality and reliability. Equally, Cyfuse Biomedical K.K. and EISCO Scientific LLC are gaining traction by offering novel approaches to bioprinting and model validation, thereby reinforcing the need for highly physiologically relevant systems.

Other key players, including Emulate Inc., Hurel Corporation, and InSphero AG, have systematically integrated emerging technologies to enhance model precision and usability. Companies like Kirkstall Ltd, MIMETAS B.V., and NeurOmics, Inc. are notable for their contributions toward merging traditional cell culture techniques with state-of-the-art engineering innovations. Organovo Holdings Inc. and Pandorum Technologies Private Limited have also been instrumental in redefining biological fabrication for comprehensive tissue modeling. Additionally, PhoenixBio Co., Ltd. and STEMCELL Technologies Inc. ensure that continuous product enhancements keep pace with evolving research demands. The cumulative impact of these organizations reflects a market driven by relentless innovation and vigorous competition, fostering an environment where quality, reliability, and scalability are equally prioritized.

The report delves into recent significant developments in the Human Liver Model Market, highlighting leading vendors and their innovative profiles. These include Ascendance Bio, BioIVT LLC, Cellink Global by BICO Group AB, CN Bio Innovations Ltd., Corning Incorporated, Cyfuse Biomedical K.K., EISCO Scientific LLC, Emulate Inc., Hurel Corporation, InSphero AG, Kirkstall Ltd, MIMETAS B.V., NeurOmics, Inc., Organovo Holdings Inc., Pandorum Technologies Private Limited, PhoenixBio Co., Ltd., and STEMCELL Technologies Inc.. Recommendations for Industry Leaders to Capitalize on Emerging Trends

Industry leaders are encouraged to adopt a multi-pronged strategy to harness the burgeoning opportunities in the human liver model sector. First, it is essential to invest in interdisciplinary collaborations that fuse expertise in tissue engineering, computational biology, and regenerative medicine. Such collaborations not only spur breakthrough innovations but also facilitate broader adoption of models that accurately mirror human physiology. Embracing state-of-the-art automation and high-throughput screening technologies will further enhance model reproducibility and accelerate preclinical studies, making your operations more competitive in the ever-evolving market landscape.

Second, consider targeting innovative product portfolio expansion strategies. Leveraging insights from advanced segmentation analyses-including model types, cell sources, application fields, and end-user profiles-can pinpoint specific market opportunities. Industry players who customize their offerings to meet sector-specific needs-whether for drug discovery or educational applications-will likely gain a strategic advantage. Additionally, scaling by addressing regional nuances is recommended; tailored regional partnerships or localized research initiatives can help capitalize on the distinct market dynamics present in the Americas, Europe, the Middle East and Africa, as well as the Asia-Pacific.

Finally, adopting rigorous validation protocols and pursuing regulatory alignment is paramount. Clear standards in model performance and reproducibility not only build trust with stakeholders but also pave the way for smoother market entry and integration into regulatory frameworks. By proactively engaging with these strategic imperatives, industry leaders will be well-positioned to drive innovation, secure market leadership, and better address emerging global health challenges.

Conclusion and Future Outlook for Human Liver Model Research

In conclusion, the advances in human liver modeling are reshaping the landscape of biomedical research and drug development. The integration of innovative techniques, from two-dimensional cultures to complex three-dimensional organoids and in silico platforms, is enabling breakthroughs that were once considered unattainable. As the market becomes increasingly segmented-by model types, cell sources, applications, and end-user demographics-the industry is poised for significant growth and diversification.

The analysis illustrates that transformative shifts are fueled by relentless innovation, cross-disciplinary collaborations, and regional strategic investments. Technological advancements in automation, high-throughput screening, and tissue engineering have raised the bar, ensuring that the models not only replicate key liver functions but also offer enhanced utility in toxicity and physiological studies. The competitive landscape, which features a blend of established giants and nimble startups, continues to drive the evolution of liver models, creating a robust foundation that supports next-generation drug discovery and clinical research.

Looking ahead, continued investments in research, a focus on scalable solutions, and adherence to robust regulatory standards will be critical. By recognizing and leveraging emerging trends, industry stakeholders will be able to navigate an increasingly complex market with precision and confidence, establishing pathways for sustained innovation and growth in the years to come.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising government and institutional funding for life sciences and toxicological studies
    • 5.1.1.2. Increase in demand for personalized medicine and patient-specific therapies
    • 5.1.1.3. Escalating prevalence of liver diseases and associated health complications
  • 5.1.2. Restraints
    • 5.1.2.1. High development and manufacturing costs of advanced liver models
  • 5.1.3. Opportunities
    • 5.1.3.1. Investments & funding in biomedical research and innovative liver simulation technologies
    • 5.1.3.2. Technological advances in tissue engineering and 3D bioprinting solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory requirements and compliance obstacles in the human liver model approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Model Type: Rising demand for 3D human liver model for their simplicity and rapid screening capabilities
  • 5.2.2. End Users: Growing usage of human liver model in biotechnology companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Liver Model Market, by Model Type

• 6.1. Introduction
• 6.2. 2D Models
• 6.3. 3D Models
• 6.4. Ex Vivo Models
• 6.5. Hybrid Models
• 6.6. In Silico Models
• 6.7. Liver Organoids

7. Human Liver Model Market, by Cell Source

• 7.1. Introduction
• 7.2. Immortalized Liver Cell Lines
• 7.3. Primary Human Hepatocytes
• 7.4. Stem Cell-Derived Models

8. Human Liver Model Market, by Application

• 8.1. Introduction
• 8.2. Drug Discovery
• 8.3. Education
  • 8.3.1. Physiological Studies
  • 8.3.2. Toxicology Studies

9. Human Liver Model Market, by End Users

• 9.1. Introduction
• 9.2. Biotech Companies
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical Companies
• 9.5. Research Laboratories

10. Americas Human Liver Model Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Human Liver Model Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Human Liver Model Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Ochre Bio and GSK join forces to accelerate hepatology drug discovery
  • 13.3.2. Boehringer Ingelheim and Ochre Bio partner to accelerate regenerative liver therapy discovery
  • 13.3.3. PhoenixBio's innovative humanized liver chimeric mouse models transform preclinical drug testing
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Ascendance Bio
• 2. BioIVT LLC
• 3. Cellink Global by BICO Group AB
• 4. CN Bio Innovations Ltd.
• 5. Corning Incorporated
• 6. Cyfuse Biomedical K.K.
• 7. EISCO Scientific LLC
• 8. Emulate Inc.
• 9. Hurel Corporation
• 10. InSphero AG
• 11. Kirkstall Ltd
• 12. MIMETAS B.V.
• 13. NeurOmics, Inc.
• 14. Organovo Holdings Inc.
• 15. Pandorum Technologies Private Limited
• 16. PhoenixBio Co., Ltd.
• 17. STEMCELL Technologies Inc.